Ravichandran, Sathyabaarathi http://orcid.org/0000-0003-2488-8617
Erra-Diaz, Fernando http://orcid.org/0000-0002-9519-5909
Karakaslar, Onur E. http://orcid.org/0000-0002-9182-910X
Marches, Radu
Kenyon-Pesce, Lisa
Rossi, Robert http://orcid.org/0000-0003-2388-5254
Chaussabel, Damien http://orcid.org/0000-0002-6131-7242
Nehar-Belaid, Djamel http://orcid.org/0000-0001-6002-5021
LaFon, David C.
Pascual, Virginia http://orcid.org/0000-0002-8806-8426
Palucka, Karolina
Paust, Silke http://orcid.org/0000-0002-0526-3999
Nahm, Moon H.
Kuchel, George A. http://orcid.org/0000-0001-8387-7040
Banchereau, Jacques
Ucar, Duygu http://orcid.org/0000-0002-9772-3066
Article History
Received: 21 April 2023
Accepted: 21 November 2023
First Online: 5 January 2024
Competing interests
: While this study was performed, J.B. served on the Board of Directors for Neovacs, is a Board of Directors member and stockholder for Ascend Biopharmaceuticals, Scientific Advisory Board member for Cue Biopharma and stockholder for Sanofi. M.H.N. is an employee of the University of Alabama at Birmingham, which has intellectual property on the target bacteria used for the opsonophagocytosis assays. S.P. serves on the Scientific Advisory Board for Shoreline Biosciences and Qihan Biotechnology and is a Scientific Consultant for Qihan Biotechnology and the Genomics Institute of the Novartis Research Foundation. The other authors declare no competing interests.